Randomized Evaluation of an Inflatable Femoral Artery Compression Device After Cardiac Catheterization |
| |
Authors: | JAN ERIK. NORDREHAUG M.D. Ph .D. NICOLAS A. F. CHRONOS M.B. B.S. KIM A. PRIESTLEY M.B. Ch .B. NIGEL P. BULLER M.B. B.S. JOHN FORAN M.B. B.S. RAY WAINWRIGHT B.Sc. M.D. MRCP STEIN EMIL. VOLLSET M.D. DRPH M.Ph . ULRICH SIGWART M.D. |
| |
Affiliation: | From the Department of Invasive Cardiology, Royal Brompton National Heart and Lung Hospital, London;The Regional Cardiac Unit, Brook Hospital, London, UK;The Section for Medical Informatics and Statistics, University of Bergen, Bergen, Norway |
| |
Abstract: | Mechanical femoral artery compression devices have several limitations. We compared a novel disposable beltheld pneumatic compression device to manual compression alone in 213 patients randomized into two equal groups. Both were comparable for age, gender, current therapy with aspirin (ASA) and warfarin, diameter of the arterial sheath, previous procedures via the same artery, procedure duration, and blood pressure. Manual compression time was 12 ± 3 minutes. Pneumatic compression was reduced during 60 minutes. Patient discomfort was assessed as none (82% vs 88%), mild (13% vs 8%), moderate (3% vs 4%), or severe (2% vs 0%) for the manual versus pneumatic group, respectively. Bleeding and hematoma occurred in 7.5% of patients with no difference between the treatment groups. However, manual compression was significantly more effective in the higher range of systolic blood pressure, and pneumatic in the lower range, with a cut point of approximately 170 mmHg. Predictors for bleeding were systolic blood pressure and dose of ASA. Among 113 patients with systolic blood pressure < 160 mmHg and low dose (75 mg) or no ASA, only / patient (0.9%) experienced bleeding while 31% of 16 patients with both elevated systolic blood pressure and high dose ASA (150–330 mg) bled. We conclude that pneumatic femoral artery compression does not reduce bleeding and hematoma compared with manual compression. The use of low dose (75 mg) or no ASA, as well as giving special attention to patients with elevated systolic blood pressure, may reduce the risk of bleeding after cardiac catheterization . |
| |
Keywords: | |
|
|